oncology fellowship training at the Memorial Sloan-Kettering Cancer Center in New York. He spent two years at the National Institutes of Health as a Howard Hughes Medical Institute-NIH Research Scholar. Agus has had a long and varied career. At the Memorial Sloan-Kettering Cancer Center in New York, he was an attending physicia

A. DOUDNA 1s a professor in the Chemistry and the Molecular and Cell Biology Departments at the University of California, Berkeley, investigator with the Howard Hughes Medical Institute, and researcher in the Physical Biosciences Division at the Lawrence Berkeley National Laboratory. She is internationally recognized as a leading exp

to Bert Vogelstein, professor and director of the Ludwig Center for Cancer Genetics and Therapeutics at the Johns Hopkins Kimmel Cancer Center and the Howard Hughes Medical Institute, a mathematical model showing the genetic evolution of pancreatic-cancer cells from initial mutation to non-primary malignant cells. What Nowak's t

to Bert Vogelstein, professor and director of the Ludwig Center for Cancer Genetics and Therapeutics at the Johns Hopkins Kimmel Cancer Center and the Howard Hughes Medical Institute, a mathematical model showing the genetic evolution of pancreatic-cancer cells from initial mutation to non-primary malignant cells. What Nowak's t

nd share their findings with physicians." In that same year, the Program of Evolutionary Dynamics presented to the John Hopkins School of Medicine, the Howard Hughes Medical Institute and others, a mathematical model showing the genetic evolution of pancreatic cancer cells from the time of initial mutation to non-primary malignan